EC approves Vertex’s Symkevi plus Kalydeco to treat CF in children aged 6-11 years

The EC has approved Vertex’s Symkevi plus Kalydeco to treat children with cystic fibrosis ages 6-11 years. (Credit: Jai79 from Pixabay)